Dr. Goldberg is a transplant hepatologist who dedicates most of his time conducting epidemiology and health services research on topics related to chronic and end-stage liver disease, organ allocation and transplantation, and organ donation. He is currently the PI/Co-PI of three R01 grants funded from the NIH (NIDDK, NIAAA) focused on developing new models to estimate the survival benefit of liver transplantation, to develop better models to predict outcomes of kidney and liver allografts, and a study of early liver transplantation for alcohol-associated liver disease. In addition, Dr. Goldberg is the Co-PI of a U01 from the NIDDK to perform a multi-center trial of transplanting kidneys from hepatitis C-infected donors into hepatitis C-negative patients, and a U01 to participate in the NIDDK-sponsored Liver Cirrhosis Network. Dr. Goldberg has published more than 150 peer-reviewed publications including first-author papers in the New England Journal of Medicine and JAMA and was the first author of the first trial focused on transplanting kidneys from hepatitis C-infected donors into hepatitis C-negative recipients followed by antiviral treatment.